Oramed Pharmaceuticals buy Jacqueline
Summary
This prediction ended on 14.03.14 with a price of €8.03. The price of Oramed Pharmaceuticals has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -28.59%. Jacqueline has 50% into this predictionOramed is a pharmaceutical company that focuses on the development of innovative oral delivery solutions for drugs that are traditionally administered through injection. The company is primarily dedicated to the development of an oral insulin capsule that can potentially revolutionize the treatment of diabetes. Their flagship product, ORMD-0801, is currently in Phase III clinical trials in the United States and has received Fast Track designation from the FDA. Oramed is a publicly traded company listed on the Nasdaq under the ticker symbol ORMP.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Oramed Pharmaceuticals | -4.022% | -4.022% | -29.746% | -87.138% |
iShares Core DAX® | -3.429% | 5.085% | 15.455% | 12.600% |
iShares Nasdaq 100 | -6.121% | 0.593% | 16.379% | 27.048% |
iShares Nikkei 225® | -7.364% | 5.479% | 6.970% | -3.061% |
iShares S&P 500 | -4.366% | 2.019% | 18.650% | 32.317% |
Comments by Jacqueline for this prediction
In the thread Oramed Pharmaceuticals diskutieren
Für Diabetiker toll, Pille statt Spritze! KZ 15€!
Der Kursabfall der letzten Tag spricht für einen Einstiegszeitpunkt. 52 Wochen Hoch am 13.01.2014 bei 22,25€ (Tradegate), das tief lag am 06.02.2014 bei 10,17€ (Tradegate). Auf negative Stimmungsmache, wie die von Feuerstein, gebe ich nicht das geringste und bin überzeugt, dass der Kurs in den nächsten Monaten mindestens auf 15€ zurückkommt.